IL252042B - Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma - Google Patents
Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinomaInfo
- Publication number
- IL252042B IL252042B IL252042A IL25204217A IL252042B IL 252042 B IL252042 B IL 252042B IL 252042 A IL252042 A IL 252042A IL 25204217 A IL25204217 A IL 25204217A IL 252042 B IL252042 B IL 252042B
- Authority
- IL
- Israel
- Prior art keywords
- inhibition
- treatment
- hepatocellular carcinoma
- ornithine aminotransferase
- gaba analogues
- Prior art date
Links
- 102000004132 Ornithine aminotransferases Human genes 0.000 title 1
- 108090000691 Ornithine aminotransferases Proteins 0.000 title 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 title 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 title 1
- 230000005764 inhibitory process Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462076980P | 2014-11-07 | 2014-11-07 | |
| PCT/US2015/059738 WO2016073983A2 (en) | 2014-11-07 | 2015-11-09 | Ornithine aminotransferase inhibition with gaba analogues for treatment of hepatocellular carcinoma |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL252042A0 IL252042A0 (en) | 2017-06-29 |
| IL252042B true IL252042B (en) | 2020-05-31 |
Family
ID=55910047
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL252042A IL252042B (en) | 2014-11-07 | 2017-04-30 | Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9603820B2 (enExample) |
| EP (1) | EP3215144B1 (enExample) |
| JP (1) | JP6867949B2 (enExample) |
| AU (1) | AU2015342801A1 (enExample) |
| CA (1) | CA2966642C (enExample) |
| ES (1) | ES2882126T3 (enExample) |
| IL (1) | IL252042B (enExample) |
| MX (1) | MX2017006022A (enExample) |
| WO (1) | WO2016073983A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019243586A1 (en) * | 2018-03-29 | 2020-10-15 | Ovid Therapeutics Inc. | Use of (1S,3S)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and (S)-3-amino-4-(difluoromethylenyl)cyclopent-1-ene-1-carboxylic acid in the treatment of eye disorders |
| US10822301B2 (en) | 2018-04-12 | 2020-11-03 | Northwestern University | 3-carbon substituted 4-aminocyclopent-1-ene-1-carboxylic acid compounds as inhibitors of gamma-aminobutyric acid (GABA) aminotransferase |
| ES2985536T3 (es) * | 2018-05-25 | 2024-11-06 | Univ Northwestern | Proceso para la síntesis del ácido (S)-3-amino-4-(difluorometilenil)ciclopent-1-eno-1-carboxílico |
| CA3102786A1 (en) | 2018-06-07 | 2019-12-12 | Ovid Therapeutics Inc. | Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid and related compounds, (1s,3s)-3-amino-4-(difluoromethylidene) cyclopentane-1-carboxylic acid and vigab atrin in the treatment of developmental disorders |
| WO2020176511A1 (en) * | 2019-02-25 | 2020-09-03 | Northwestern University | Analogs of 3-amino-4-(propan-2-ylidene) cyclopentane-1-carboxylic acid and uses thereof for treating diseases and disorders associated with ornithine aminotransferase activity |
| WO2020206234A1 (en) * | 2019-04-03 | 2020-10-08 | Northwestern University | 2-difluoro substituted 4-aminocyclopentanecarboxylic acids as inhibitors of gamma-aminobutyric acid aminotransferase and human ornithine aminotransferase |
| US11993569B2 (en) | 2020-01-23 | 2024-05-28 | Northwestern University | 3-amino-4-halocyclopentene carboxylic acids as inactivators of aminotransferases |
| CN117321025A (zh) * | 2021-03-03 | 2023-12-29 | 西北大学 | 作为人鸟氨酸氨基转移酶的选择性灭活剂的(s)-3-氨基-4,4-二卤代环戊-1-烯甲酸 |
| JP2024515306A (ja) * | 2021-04-20 | 2024-04-08 | バイスクルテクス・リミテッド | Ｐ－セレクチンに特異的な二環式ペプチドリガンド |
| WO2023023276A1 (en) * | 2021-08-19 | 2023-02-23 | N1 Life, Inc. | Taxol conjugate compounds, pharmaceutical compositions comprising the same, and methods for their use |
| WO2024196851A1 (en) * | 2023-03-17 | 2024-09-26 | Northwestern University | Bicyclic compounds as inactivators of oat and gaba-at |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6794413B1 (en) | 2002-07-19 | 2004-09-21 | Northwestern University | Compounds and related methods for inhibition of γ-aminobutyric acid aminotransferase |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| IL177609A (en) | 2006-08-21 | 2015-11-30 | Yaron Ilan | Use of gobacoline or its analogue to produce a drug to treat liver carcinoma |
-
2015
- 2015-11-09 WO PCT/US2015/059738 patent/WO2016073983A2/en not_active Ceased
- 2015-11-09 CA CA2966642A patent/CA2966642C/en active Active
- 2015-11-09 MX MX2017006022A patent/MX2017006022A/es unknown
- 2015-11-09 JP JP2017543338A patent/JP6867949B2/ja active Active
- 2015-11-09 ES ES15856956T patent/ES2882126T3/es active Active
- 2015-11-09 AU AU2015342801A patent/AU2015342801A1/en not_active Abandoned
- 2015-11-09 US US14/936,153 patent/US9603820B2/en active Active
- 2015-11-09 EP EP15856956.6A patent/EP3215144B1/en active Active
-
2017
- 2017-04-30 IL IL252042A patent/IL252042B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| JP2017533964A (ja) | 2017-11-16 |
| ES2882126T3 (es) | 2021-12-01 |
| WO2016073983A3 (en) | 2016-08-11 |
| EP3215144A2 (en) | 2017-09-13 |
| EP3215144B1 (en) | 2021-04-28 |
| CA2966642A1 (en) | 2016-05-12 |
| US20160128958A1 (en) | 2016-05-12 |
| MX2017006022A (es) | 2017-11-17 |
| AU2015342801A1 (en) | 2017-05-18 |
| WO2016073983A2 (en) | 2016-05-12 |
| CA2966642C (en) | 2023-03-28 |
| IL252042A0 (en) | 2017-06-29 |
| EP3215144A4 (en) | 2018-06-20 |
| US9603820B2 (en) | 2017-03-28 |
| JP6867949B2 (ja) | 2021-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL252042B (en) | Ornithine aminotransferase inhibition with gaba analogs for the treatment of hepatocellular carcinoma | |
| IL285154A (en) | Therapeutic inhibitor of lactate dehydrogenase and their factors | |
| ZA201604272B (en) | Inhibitors of glutaminase | |
| IL258516A (en) | (s)-3-Amino-4-(difluoromethylnyl)cyclopent-1-en-1-carboxylic acid and related compounds as GABA aminotransferase inhibitors for the treatment of epilepsy, addiction and hepatocellular carcinoma | |
| IL249476A0 (en) | Combined treatment with glutaminase inhibitors | |
| SG11201708034SA (en) | Methods of administering glutaminase inhibitors | |
| ZA201700183B (en) | Acetylcholinesterase inhibitors for treatment of dermatological conditions | |
| EP3107538A4 (en) | Combination therapy for hepatocellular carcinoma | |
| SG11201508419PA (en) | Compositions and methods for detection and treatment of hepatocellular carcinoma | |
| SG10201407557VA (en) | Therapeutic biologic for treatment of hepatocellular carcinoma | |
| IL264950B1 (en) | Combined treatments for the treatment of malignant liver cell carcinoma | |
| IL258876B (en) | Treatment of fatty liver associated with low ovulation | |
| PL3142641T3 (pl) | Preparaty do leczenia nadczynności tarczycy | |
| HUS2500045I1 (hu) | Etilén-glikolok MMF származékai | |
| IL250846A0 (en) | Synthesis of cyclocreatin and its analogs | |
| GB201412010D0 (en) | Treatment of hypertransaminasemia | |
| ZA201408372B (en) | Therapeutic biologic for treatment of hepatocellular carcinoma | |
| IL250599A0 (en) | The composition for the treatment of arthritis and osteoarthritis | |
| GB201513922D0 (en) | Treatment of hyperpigmentation | |
| GB201613350D0 (en) | Treatment of hyperpigmentation | |
| GB201522936D0 (en) | A combination of Chinese medicine treating fatty liver | |
| GB201523020D0 (en) | The combination of traditional chinese medicine for the treatment of paronychia | |
| GB201603755D0 (en) | Treatment of hypothyroidism | |
| GB201603752D0 (en) | Treatment of hypothyroidism | |
| AP2016009662A0 (en) | Combination of taurine and racemethionine for treatment of liver diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |